Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report)'s stock had its "overweight" rating reaffirmed by Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They currently have a $25.00 target price on the stock. Cantor Fitzgerald's price objective indicates a potential upside of 214.86% from the stock's previous close.
ZVRA has been the subject of a number of other research reports. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday. Canaccord Genuity Group lowered their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, November 14th. Guggenheim set a $21.00 price objective on Zevra Therapeutics and gave the company a "buy" rating in a research report on Tuesday, February 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $22.14.
Get Our Latest Report on ZVRA
Zevra Therapeutics Price Performance
Shares of ZVRA traded up $0.02 during mid-day trading on Wednesday, reaching $7.94. The stock had a trading volume of 612,026 shares, compared to its average volume of 418,269. The business has a fifty day moving average of $7.93 and a 200 day moving average of $8.14. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm has a market cap of $423.81 million, a price-to-earnings ratio of -4.03 and a beta of 1.98. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $12.00 million during the quarter, compared to analysts' expectations of $8.93 million. Equities analysts predict that Zevra Therapeutics will post -1.95 EPS for the current year.
Insider Buying and Selling
In other Zevra Therapeutics news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the completion of the sale, the executive vice president now directly owns 29,486 shares of the company's stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock worth $674,176 in the last three months. 2.40% of the stock is owned by insiders.
Institutional Trading of Zevra Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. increased its position in Zevra Therapeutics by 462.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock valued at $30,441,000 after buying an additional 3,001,000 shares in the last quarter. FMR LLC raised its position in shares of Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company's stock valued at $16,054,000 after purchasing an additional 2,312,384 shares during the last quarter. AIGH Capital Management LLC acquired a new stake in Zevra Therapeutics in the 4th quarter worth approximately $6,577,000. Stonepine Capital Management LLC acquired a new position in Zevra Therapeutics during the 3rd quarter valued at approximately $4,858,000. Finally, Vestal Point Capital LP purchased a new position in shares of Zevra Therapeutics in the third quarter worth $3,644,000. Hedge funds and other institutional investors own 35.03% of the company's stock.
About Zevra Therapeutics
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Further Reading
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
